Conjugates of a cell-binding molecule with camptothecin analogs
Water-soluble camptothecin analogs conjugated with cell-binding molecules address insolubility and aggregation issues, enhancing therapeutic efficacy and safety in targeted therapies.
AU2020444233B2Pending Publication Date: 2026-07-09HANGZHOU DAC BIOTECH CO LTD
Patent Information
- Authority / Receiving Office
- AU · AU
- Patent Type
- Applications
- Current Assignee / Owner
- HANGZHOU DAC BIOTECH CO LTD
- Filing Date
- 2020-06-19
- Publication Date
- 2026-07-09
AI Technical Summary
Technical Problem
Existing camptothecin analogs used in antibody-drug conjugates (ADCs) face issues with insolubility and aggregation, leading to systemic side-effects and limited clinical success, despite their potential as potent cytotoxic agents.
Method used
Development of water-soluble camptothecin analogs conjugated with cell-binding molecules through specific linkers, ensuring stability in blood circulation and targeted cell death upon release.
Benefits of technology
The conjugates achieve enhanced therapeutic efficacy with reduced side-effects by maintaining solubility and stability, allowing for effective targeted cancer, autoimmune disease, and infectious disease treatment.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 00000407_0000 
Figure 00000408_0000 
Figure 00000408_0001
Abstract
Provided are conjugates of camptothecin analogs with a cell-binding molecule of formula (I), wherein R1, R2, R3, R4, R5, X, L, n, m, T and ----- are defined herein. It also provides methods of making the conjugates of camptothecin analogs to a cell-binding agent, as well as methods of using the conjugates in targeted treatment of cancer, infection, and immunological disorders.
Need to check novelty before this filing date? Find Prior Art